3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
311
Neoplasm Metastasis
38
Neoplasms
22
Advanced Breast Cancer
19
Ovarian Neoplasms
18
Carcinoma, Non-Small-Cell Lung
14
Endometrial Neoplasms
11
Prostatic Neoplasms
10
Hereditary Sensory and Autonomic Neuropathies
10
Triple Negative Breast Neoplasms
8
Colorectal Neoplasms
6
Breast Cancer Metastatic
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Recurrence
5
Carcinoma, Ovarian Epithelial
5
Neoplasms by Site
4
Multiple Endocrine Neoplasia Type 1
4
Breast Diseases
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Lobular
3
Uterine Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Interventions
Carboplatin
69
Paclitaxel
47
Radiotherapy
44
Pemetrexed
42
Cisplatin
41
Bevacizumab
36
Gemcitabine
27
Docetaxel
27
Erlotinib Hydrochloride
23
Gefitinib
18
pembrolizumab
14
Taxes
13
Vinorelbine
10
Cetuximab
10
Radiation
8
Nivolumab
8
Magnetic Resonance Spectroscopy
8
Radiosurgery
7
Platinum
7
Etoposide
7
Surgical Procedures, Operative
6
Radiotherapy, Conformal
6
ceritinib
5
capmatinib
5
aflutinib
5
Specimen Handling
5
Neoadjuvant Therapy
5
Mastectomy, Segmental
5
Cyclophosphamide
5
tislelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma of Lung
×
Fulvestrant
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled